CG Bio and CG Medtech Present Next-Generation Spinal Treatment Strategy at GSC 2026

Introducing Next-Generation Spinal Treatment Strategies Combining Robot Navigation-Based Minimally Invasive Surgery and Bone Regeneration Technologies at GSC 2026 in Istanbul

CG Bio, a company specializing in regenerative medicine, and its subsidiary CG Medtech announced on June 4 that they participated in the Global Spine Congress 2026 (GSC 2026), held in Istanbul, Türkiye, from May 27 to 30. During the event, the companies introduced their next-generation spinal treatment strategy to global medical professionals, which combines robot navigation-based minimally invasive spinal surgery with rhBMP-2-based bone regeneration therapy.

On-site at the GSC 2026 Endoscopy Workshop by CG Bio. CG Bio

The GSC is an international spine academic congress organized by AO Spine. It serves as a global academic platform where spine surgeons, researchers, and medical professionals from around the world share the latest surgical techniques and clinical research findings.

At this year’s congress, CG Bio and CG Medtech presented an integrated portfolio covering spinal surgery, bone fusion, and bone regeneration therapies. In particular, they attracted attention from global medical professionals by showcasing an integrated treatment strategy centered on the "CUVIS-Spine" robotic navigation system, which links endoscopic spinal surgery devices, spinal implants, and rhBMP-2-based bone fusion solutions.

At the exhibition booth, CG Bio’s major product lines in the spine and bone regeneration fields were introduced, including "EXCENDER," "NOVOMAX Fusion," "NOVOSIS," and "CUVIS-Spine," as well as CG Medtech’s "INNOVERSE Screw." Notably, the integrated portfolio that combines CG Medtech’s minimally invasive spinal surgery solutions with CG Bio’s bone fusion and regenerative medicine technologies was highlighted as a next-generation spinal treatment strategy aiming to enhance surgical accuracy while reducing the recovery burden on patients.

This academic event also featured hands-on training programs for global medical professionals, such as "Endoscopic Workshops," along with clinical sessions. In the practical training session led by Professor Ko Yong-San of Kyungpook National University Hospital, participants were introduced to minimally invasive spinal surgery techniques such as robot-assisted endoscopic decompression using CUVIS-Spine and unilateral biportal endoscopic lumbar interbody fusion (UBE-LIF).

Yoo Hyun-Seung, CEO of CG Bio, stated, "CG Bio has built an integrated portfolio that encompasses spinal implants, minimally invasive surgical solutions, and rhBMP-2-based bone regeneration therapies." He added, "Through this year’s GSC 2026, we were able to not only share clinical experiences with global medical professionals but also further strengthen our foundation for expanding into the European, Middle Eastern, and Asian markets."

He went on to say, "Going forward, we will continue to expand clinical value and brand trust in the global spinal treatment market by offering differentiated solutions that combine robot navigation-based spinal surgery and regenerative medicine technologies."

This content was produced with the assistance of AI translation services.